Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 28;1(2):e36.
doi: 10.4081/rt.2009.e36.

Treatment outcome of maxillary sinus cancer

Hye Sung Won  1 , Sang Hoon Chun, Bum-Soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Dong-Il Sun, Min Sik Kim, Jin-Hyoung Kang
Affiliations

Treatment outcome of maxillary sinus cancer

Hye Sung Won et al. Rare Tumors. .

Abstract

The standard treatment in the early stage of maxillary sinus cancer is surgical resection followed by postoperative radiation therapy. However, for locally advanced maxillary sinus cancer, a multimodality treatment approach is strongly recommended to improve the survival rate and quality of life of the patient. We determined the treatment outcomes of induction chemotherapy, concurrent chemoradiation therapy, and surgical resection for locally advanced maxillary sinus cancer. Forty-four patients with locally advanced maxillary sinus cancer, who had been treated between January 1990 and April 2008 at Kangnam St. Mary's Hospital, were retrospectively analyzed. The objective response rates were 70%, 53%, and 57% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and concurrent chemoradiation therapy groups, respectively. The orbital preservation rates were 83%, 100%, and 75% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and surgical resection groups, respectively. In seven of nine patients in whom the orbit could be preserved after induction chemotherapy, the primary tumors were removed completely. However, although the orbits were preserved in three patients who underwent surgical resection as a primary treatment, all three cases were confirmed to be incomplete resections. We found that active induction chemotherapy for locally advanced cancer of the maxillary sinus increased the possibility of complete resection with orbital preservation as well as tumor down-staging.

Keywords: induction chemotherapy; intra-arterial chemotherapy; maxillary sinus cancer; organ preservation..

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: the authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Orbital preservation and complete resection rate according to treatment modalities. IA-ICT: intra-arterial induction chemotherapy, IV-ICT: intravenous induction chemotherapy.
Figure 2
Figure 2
Overall survival curve of 44 patients with maxillary sinus malignancies by the Kaplan-Meier method.
Figure 3
Figure 3
A case of a T4b maxillary sinus cancer patient with: (A) magnetic resonance imaging at diagnosis; (B) magnetic resonance imaging after completion of three cycles of intra-arterial induction chemotherapy with cisplatin and intravenous 5-FU; (C) magnetic resonance imaging six months after total maxillectomy with flap reconstruction.
See this image and copyright information in PMC

References

    1. Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92:3012–29. - PubMed
    1. Spiro JD, Soo KC, Spiro RH. Squamous carcinoma of the nasal cavity and paranasal sinuses. Am J Surg. 1989;158:328–32. - PubMed
    1. Nishino H, Ichimura K, Tanaka H, et al. Results of orbital preservation for advanced malignant maxillary sinus tumors. Laryngoscope. 2003;113:1064–9. - PubMed
    1. Samant S, Robbins KT, Vang M, et al. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg. 2004;130:948–55. - PubMed
    1. Monnerat C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 2002;13:995–1006. - PubMed

LinkOut - more resources